Crux Biomedical The company is developing a retrievable Inferior Vena Cava (IVC) Filter that promises to be a great improvement over existing modes of treatment. The device has been successfully tested in animal studies in 2006 and was recently implanted in humans. Crux is currently working with the FDA to design and implement large-scale human clinical trials. The clinical trials should begin in March 2007.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/30/07 | Series B | 2.25M | MTI, Imagination Technologies Group, Killik & Co, Royal Dutch Shell Group | Unknown |
People
Murli Srinivasan (Director of Operations)
Eric Johnson (VP R&D)
Mel Schatz (CEO)
Christopher Schaffer (CFO)
Douglas Kelly (Board member)
News
Crux pumps in $8M to prevent embolisms
January 23, 2009 7:38 am
Crux Biomedical has raised $8 million in second-round funding to cover its debt and finalize clinical trials on its device… Continue reading ⟩
Crux, a medical device company, raises $3.85M
September 27, 2006 11:30 am
Crux Biomedical Inc., a Portola Valley, Calif.-based medical device startup from former NeoPath and Bacchus Vascular executive Mel Schatz, has… Continue reading ⟩